Autoimmune diseases are caused by pathogenic antibody and/or T-cell responses that are left unchecked by regulatory immune mechanisms. Recent studies in immunology have focused on subsets of regulatory T cells (T(regs)) that can suppress autoimmune responses. Invariant natural killer T (iNKT) cells are a subset of T(regs) that recognize glycolipid antigens in the context of CD1d proteins. iNKT cells play a suppressive role in several autoimmune diseases and, therefore, are attractive targets for development of immunotherapies for these diseases. While preclinical studies with reagents, such as the sea sponge-derived iNKT-cell antigen alpha-galactosylceramide, have been promising, there are substantial concerns about treating humans with autoimmunity, or at risk of developing autoimmunity, with these reagents.
No takes yet. Share an insight, caveat, or question.
Luc Van Kaer (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: